Arsta, Sweden

Camilla Niva

USPTO Granted Patents = 5 

 

Average Co-Inventor Count = 10.0

ph-index = 2

Forward Citations = 13(Granted Patents)


Company Filing History:


Years Active: 2017-2025

Loading Chart...
Loading Chart...
5 patents (USPTO):Explore Patents

Title: Camilla Niva: Innovator in Amyloid Beta Research

Introduction

Camilla Niva is a prominent inventor based in Arsta, Sweden. She has made significant contributions to the field of biomedical research, particularly in the development of antibodies targeting amyloid beta peptides. With a total of 5 patents to her name, Niva is recognized for her innovative approaches to treating conditions associated with amyloidosis, including Alzheimer's disease.

Latest Patents

Niva's latest patents focus on antibodies that selectively bind to human amyloid beta 42 peptide over human amyloid beta 40 peptide. These antibodies are designed as therapeutic agents for binding amyloid beta 42 peptide, which is crucial in treating conditions related to amyloidosis. Her work aims to provide new avenues for addressing the challenges posed by Alzheimer's disease and similar disorders.

Career Highlights

Throughout her career, Camilla Niva has been associated with Medimmune Limited, where she has been instrumental in advancing research on amyloid beta. Her innovative work has positioned her as a key figure in the field, contributing to the understanding and potential treatment of neurodegenerative diseases.

Collaborations

Niva collaborates with talented professionals in her field, including Maria Groves and Suzanne Gustavsson. These partnerships enhance her research efforts and contribute to the development of effective therapeutic solutions.

Conclusion

Camilla Niva's contributions to the field of amyloid beta research highlight her role as an influential inventor. Her innovative patents and collaborations reflect her commitment to advancing medical science and improving patient outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…